Downloads: 1
[0ba121]:
/
the_basic_characteristics.xlsx
| # | Clinical trial information | First author | Year | Phase | Histology | Treatment | Number of patients | Age in years(median) | Male(%) | Current or former smoking(%) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02041533 | D.P. Carbone | 2017.0 | III | NSCLC | nivolumab | 271 | 63.0 | 68.0 | 88.0 |
| 2 | nan | nan | nan | nan | nan | platinum-based chemtherapy | 270 | 65.0 | 55.0 | 87.0 |
| 3 | NCT02142738 | Martin Reck | 2016.0 | III | NSCLC | pembrolizumab | 154 | 64.5 | 59.7 | 96.8 |
| 4 | nan | nan | nan | nan | nan | platinum-based chemtherapy | 151 | 66.0 | 62.9 | 87.4 |
| 5 | NCT02220894 | Tony S K Mok | 2019.0 | III | NSCLC | pembrolizumab | 637 | 63.0 | 71.0 | 78.0 |
| 6 | nan | nan | nan | nan | nan | platinum-based chemotherapy | 637 | 63.0 | 71.0 | 78.0 |
| 7 | NCT02578680 | L.Gandhi | 2018.0 | III | nonsquamous NSCLC | pembrolizumab plus pemetrexed and a platinum-based drug | 410 | 65.0 | 62.0 | 88.3 |
| 8 | nan | nan | nan | nan | nan | placebo plus pemetrexed and a platinum-based drug | 206 | 63.5 | 52.9 | 87.9 |
| 9 | NCT02039674 | Hossein Borghaei | 2018.0 | II | nonsquamous NSCLC | pembrolizumab plus carboplatin and pemetrexed | 60 | 62.5 | 37.0 | 75.0 |
| 10 | nan | nan | nan | nan | nan | carboplatin and pemetrexed | 63 | 63.2 | 41.0 | 86.0 |
| 11 | NCT02775435 | Luis G. Paz-Ares | 2018.0 | III | squamous NSCLC | pembrolizumab plus carboplatin and paclitaxel/nab-paclitaxel | 278 | 65.0 | 79.1 | 92.1 |
| 12 | nan | nan | nan | nan | nan | placebo plus carboplatin and paclitaxel/nab-paclitaxel | 281 | 65.0 | 83.6 | 93.2 |
| 13 | NCT02477826 | Hossein Borghaei | 2018.0 | III | NSCLC | nivolumab plus platinum-doublet chemotherapy | 177 | 64.0 | 73.0 | 84.0 |
| 14 | nan | nan | nan | nan | nan | platinum-doublet chemotherapy | 186 | 64.0 | 67.0 | 85.0 |
| 15 | NCT02367794 | Robert M. Jotte | 2018.0 | III | squamous NSCLC | atezolizumab plus carboplatin and nab-paclitaxel | 343 | 65.0 | 81.0 | 91.0 |
| 16 | nan | nan | nan | nan | nan | carboplatin and nab-paclitaxel | 340 | 65.0 | 82.0 | 93.0 |
| 17 | NCT02657434 | Vassiliki A. Papadimitrakopoulou | 2018.0 | III | nonsquamous NSCLC | atezolizumab plus carboplatin/cisplatin and pemetrexed | 292 | 64.0 | 65.8 | 87.3 |
| 18 | nan | nan | nan | nan | nan | carboplatin/cisplatin and pemetrexed | 286 | 63.0 | 67.1 | 89.5 |
| 19 | NCT02367781 | Howard West | 2019.0 | III | nonsquamous NSCLC | atezolizumab plus carboplatin plus nab-paclitaxel | 483 | 64.0 | 57.0 | 87.0 |
| 20 | nan | nan | nan | nan | nan | carboplatin plus nab-paclitaxel | 240 | 65.0 | 58.0 | 92.0 |